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savings were 12,118,232BRL/year for the public health care system or 1,348BRL/year 
per 1,000 admissions. CONCLUSIONS: RCI has shown similar efﬁ cacy when com-
pared to RCC with fewer costs. The cost difference was mild in magnitude but when 
extrapolated to a large-scale perspective these results reinforce the need of evidence-
based decision making and rational resource allocation.
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OBJECTIVES: In Germany, the ﬁ nancing mechanism aggravates the cost issue of so 
called high-utilizers. So far, there were no care management concepts as the mostly 
multimorbid, complex medical conditions were judged as individual, non-inﬂ uenceable 
cases. We developed a method to reveal issues in treatment and care of this special 
insurance population to increase efﬁ ciency. METHODS: The most critical challenge for 
insurance companies lies in the identiﬁ cation of relevant insured, in order to speciﬁ cally 
target the high effort of control and management. In this project we analyzed the second-
ary data of the members of a German insurance company in the course of four years. 
Based on this we ﬁ rst differentiated high-utilizers from average-utilizers. In the following 
we deﬂ ected by which means existing care management concepts could be comple-
mented. Based on the longterm data observation we developed a prognostic model to 
predict future high-utilizers. RESULTS: High-utilizers were deﬁ ned as the 5% most 
expensive insurance-members, who generated 50% of total spending. We distinguished 
high-utilizers who caused the main costs in one speciﬁ c care sector (pharmaceuticals and 
hospital) and patients who caused costs in multiple sectors (transsectoral). In addition, 
ultra high-utilizers were considered separately due to their extreme cost provocation. 
While it is possible to manage the ﬁ rst two groups by a combination or extension of 
existing cost reduction measures and care approaches such as disease management 
programs, ultra high-utilizers should be addressed by an individual and speciﬁ cally 
developed case management. CONCLUSIONS: This segment of insured demands a 
stringent, integrated approach in order to efﬁ ciently employ the available ﬁ nancial 
resources. This study aims to explain a practical system for the controlling and manage-
ment of expenses caused by high-utilizers based on our conclusion that the early iden-
tiﬁ cation and the speciﬁ c management of high-utilizers in health care holds high ﬁ nancial 
potential and targeted programs are promising for care optimization.
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OBJECTIVES: The purpose of this study was to determine the unit cost of the main 
production centers of Ankara University Faculty of Medicine Hospitals in 2008. 
METHODS: Expenses and costs of the two hospitals of Ankara University (Ibni Sina 
and Cebeci Hospitals) were obtained from the Hospital Information System and 
Revolving Fund distributed to the main production centers by using a step-down 
allocation method with ﬁ ve allocation steps. Unit costs were calculated in the last step. 
To determine the cost for outpatient and inpatient units, the data from the ﬁ fth alloca-
tion including the number of outpatients and inpatients as well as the number of 
inpatient days was used. RESULTS: The total cost of Ibni Sina Hospital (a 931-bed 
facility) and Cebeci Hospital (a 1153-bed facility) were calculated as c55,137,708.41 
and c49,709,800.84 respectively. In Ibni Sina Hospital, among outpatient units, Dept. 
of Hematology had the highest, while the Aphaeresis Unit had the lowest cost. As to 
the inpatient unit costs, Dept. of Internal Diseases had the highest, and Dept. of Ear, 
Nose and Throat had the lowest cost. In Cebeci Hospital, Dept. of Algology had the 
highest outpatient unit cost, and Consultation-Liaison Psychiatry had the lowest 
outpatient unit cost. In terms of number of inpatients, Dept. of Pediatrics had the 
highest, while the Aphaeresis Unit had the lowest unit cost. Nuclear Medicine Depart-
ment had the highest cost, while the Aphaeresis Unit had the lowest clinic unit cost 
with respect to inpatient hospital days. CONCLUSIONS: The results of this study 
show that the unit costs of outpatient clinics are higher in the departments of internal 
medicine compared to the departments of surgery whereas the reverse is true for 
inpatient clinics. Being aware of unit costs in a large-size hospital would improve 
strategic decision-making process including effective ﬁ nancial management, health 
care service planning and human resources management.
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OBJECTIVES: Budget impact (BI) of orphan drugs (ODs) has increased over the past 
10 years as more ODs entered the market since the introduction of the EU Regulation 
on Orphan Medicinal Products. The aim of this study is to determine the BI of ODs 
in a selection of countries where a large number of authorized ODs are reimbursed. 
METHODS: Public data on OD expenditure in Denmark was collected. The BI was 
calculated per product for the period 2005–2009. Subgroup analyses were performed 
for different types of treatment setting and ATC classes. The results of Denmark were 
compared to data collected for France (total OD costs for 2002–2009 speciﬁ ed per 
treatment setting) and for Belgium (budget estimates per product for 2008). RESULTS: 
Total BI of ODs in Denmark increased from 20.3Mc for 13 reimbursed ODs out of 
22 (59%) authorized ODs in 2005 to c58.3M for 41 out of 60 (68%) authorized ODs 
in 2009. Highest costs were for oncology drugs (57%–67% of total BI in 2005–2009) 
and for metabolism drugs (19%–30% in 2005–2009). Outpatient drugs accounted 
for 0.01% (2005) to 1.55% (2009) of total BI of ODs. In France, 34 ODs were 
reimbursed in 2008 and the BI increased from c71M in 2002 to c496M in 2008. In 
2008, the BI represented 1.8% of the total value of drugs sold. The situation in 
Belgium is comparable as the total BI of ODs was c66.2M in 2008 representing 2% 
of total reimbursed drug costs. CONCLUSIONS: Although cost per patient is rela-
tively high, total BI for a country is still modest as a result of lower volumes used. 
The results show a consistent picture for OD expenditure across different health care 
systems. Budget restrictions are not widely used for ODs but this might change when 
the anticipated increase in BI of ODs becomes more apparent.
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OBJECTIVES: At the 2000 Lisbon Summit, the European Council set the quantitative 
target to increase R&D investment in all EU countries to 3% GDP by 2010. Today, 
there is growing emphasis on innovation in R&D, particularly in the development of 
pharmaceuticals, with the European Innovation Scoreboard (EIS) publishing annual 
ranking of the 27 EU member states to track and benchmark innovation performance. 
This work aims to explore the potential relationship between R&D investment and EIS 
innovation performance. In addition, the impact of national or regional innovation 
plans/policy will be considered. METHODS: The EIS innovation performance results 
for 2009 (based on data from 2005) were identiﬁ ed as the primary measure of innova-
tion performance. The EIS includes 7 dimensions to accommodate the diversity of 
innovation processes and models that occur in varying national contexts. Eurostat data 
were used to identify the R&D investment in 2005. In order to identify the importance 
of R&D investment (%GDP) to EIS position, a simple quantitative linear regression was 
conducted. Supplementary qualitative literature searches were conducted to identify 
national and regional innovation plans and policies. RESULTS: The simple linear regres-
sion revealed a signiﬁ cant (P < 0.00005) relationship between R&D investment and 
position within the EIS innovation performance, with R&D investment explaining 72% 
of the scoreboard results. However, other dimensions have a noteworthy effect on 
innovation performance, since although the UK was identiﬁ ed as an innovation leader 
(along with Denmark, Finland, Germany, and Sweden), the UK ranks only 8th in terms 
of %GDP R&D investment. In this case, the presence of a national plan for innovation, 
alongside other factors, has led to high innovative performance. CONCLUSIONS: 
Although R&D has a signiﬁ cant effect on innovation performance, other dimensions 
also have a noteworthy effect. For example, the presence of national plans for innovation 
may aid a country in gaining innovation leader status.
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OBJECTIVES: The primary aim was to determine the extent of provision of Pharma-
cist Initiated Therapy (PIT) services in pharmacies in South Africa and the time it takes 
to provide this service. METHODS: A national research project was undertaken 
during 2008 by the South African Pharmacy Council on the services for which a 
pharmacist may levy a fee. The focus of this study is on one component of the larger 
study, namely the PIT service. RESULTS: A total of 369 pharmacies provided PIT 
services, and 3133 PIT services (cases) were measured. The majority were delivered 
by community (retail) pharmacies (95.79%). The PIT service was divided into three 
phases: Phase I (pre-administration procedure), Phase II (preparation and labelling of 
the prescribed medicine) and Phase III (provision of information and instructions to 
the patient to ensure the safe and effective use of medicine). Phase I was performed 
in 98.21% of cases, Phase II in 97.19% of cases and Phase III in 91.67% of cases. 
Pharmacists mostly delivered all three phases themselves (over 70% of cases). The 
weighted average time it took for a PIT service to be delivered was 199.02 seconds 
(just under 3.5 minutes) (SEM = 5.57 seconds). The weighted average time in com-
munity pharmacies was slightly less (192.82 seconds) compared to 312.15 seconds in 
private institutional pharmacies. The time taken was dependent on the number of 
items dispensed. The weighted average time taken was 160.76 seconds if there was 1 
item dispensed, 220.31 seconds for more than 1 and equal to 2 items dispensed, and 
327.19 seconds if more than 2 items were dispensed. a pharmacist may currently 
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charge a fee of R35.00 for this service. CONCLUSIONS: PIT is an important service 
that pharmacists deliver where the need exists. It is recommended that pharmacists be 
encouraged to counsel patients thoroughly when delivering a PIT service.
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OBJECTIVES: To examine drug cost containment policy implemented at a hospital in 
southern Thailand. METHODS: This study was a retrospective, pre-post policy inter-
vention descriptive design. During the ﬁ scal years of 2005 and 2009, various drug cost 
containment strategies, including generic substitution for any drug group and a success-
ful treatment guideline for orthopedic drugs, were adopted at a hospital in southern 
Thailand. Drug expenditures across those ﬁ scal years were examined. The expenditure 
proportions between drugs listed and unlisted in National Essential Drug List were 
calculated. Cost-saving analysis of all generic substitution was conducted. Since the 
treatment guideline for orthopedic drugs was available in the hospital, their expenditures 
were also examined. RESULTS: Total drug expenditures had increased with decreasing 
rate across the study years. It increased by 47.15% from year 2005 to 2006, 43.19% 
from year 2006 to 2007, 21.17% from year 2007 to 2008 and 2.17% from year 2008 
to 2009. The expenditures of essential drugs in the National Drug List were accounted 
for 61.64%, 56.62%, 54.38%, 48.67% and 50.94% across those study periods, respec-
tively. Results showed that generic drug substitution policy reduced overall drug expen-
ditures by 34.33%, or 7.66 million baths from year 2008. In 2009, only 11 items of 
generic drug substitution for branded-name drugs could reduce drug expenditures by 
13.33%, or 4.73 million bahts which reﬂ ected annual cost-saving about 25.95 million 
bahts. In the same year, a result showed that the implementation of orthopedic drug 
guideline reduced drug expenditures by 5.53% or 2.10 million bahts. CONCLUSIONS: 
The study indicated that treatment guideline and generic drug substitution policies could 
control relatively high amount of drug expenditures at a hospital in southern Thailand. 
Hospital administrators should consider to continue these policies.
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OBJECTIVES: The aim of this study was to asess the annual health insurance reim-
bursement of of dental health service in Hungary. METHODS: The assessment base 
of the study was the annual reports of National Health Insurance Fund Administration 
(OEP). Only the data collected from the services in conctractual relationship with the 
OEP and delivered in 2008 were evaluated. Dental care services are organised in dif-
ferent levels: general dental service, specialist dental care, special dental care on uni-
versity level and inpatient departments. Our study covers primary, outpatient and 
hospital dental care. RESULTS: Dental care was supplied by 3378 general and special-
ist dental care services until the end of 2008. For the hospital treatment of more serious 
cases 17 inpatient department is available with 154 patient beds. Within the period 
of examination (2008) 7.6 million cases or rather 23.6 million interventions were 
carried out. The health insurance expenditures of the OEP for outpatient dental care 
was 23.9 billion forints (c85,18 million). The total health insurance reimbursement 
of dental care (including primary, outpatient and hospital care) was 24.92 billion 
Hungarian forints (c88.82 million) in 2008. CONCLUSIONS: The health insurance 
reimbursement of dental care services in Hungary is approximately 2% of the total 
health insurance expenditure of OEP.
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OBJECTIVES: There is a known concern of health researchers and public managers in 
Brazil with the population’s access to medicines. We quantiﬁ ed the public expenditure 
on medicines in Brazil, during the period of 2005 to 2008. METHODS: The expenditure 
on medicines comes from a data warehouse of the Ministry of Planning, Budget and 
Management that stores the information concerning any purchase made by the Brazilian 
Federal Government. We also computed the amounts transferred to ofﬁ cial laboratories 
to produce medicines. Information on the states, Federal District and municipalities 
came from the Information System on Public Health Budget (SIOPS). RESULTS: In the 
period 2005 to 2008, the public spending with drugs rose from US$ 1.8 billion to US$ 
2.0 billion in real terms, with an average annual growth equivalent to 3%. The average 
spending in this period was US$ 1.8 billion. Most of the spending on medicines is 
attributed to the Federal Government, with values exceeding US$ 835 million per year. 
Just under half of the expenditure is given to states and municipalities. Considering only 
the federal spending, the “strategic component” represents the largest share, with par-
ticipation from 56%–64% in the period. This result is expected, since the Ministry of 
Health is responsible for funding all the medicines from the “strategic component” of 
pharmaceutical care which includes, among others, the antiretroviral drugs and blood 
products. The amounts of transfers to ofﬁ cial laboratories ranged between 20–25% of 
drug costs. CONCLUSIONS: The expenditure for those pharmaceutical care programs 
whose purchases are centralized at the federal Ministry of Health, didn’t show a signiﬁ -
cant increase in the period of 2005–2008. Rather, the evidence suggests relative stability 
of procurement of medicines from pharmaceutical care programs under the Federal 
Government’s responsibility in this period.
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OBJECTIVES: The aim of our study is to calculate the average health insurance reim-
bursement of spa treatment according to counties in Hungary. METHODS: Data were 
derived from the Hungarian National Health Insurance Fund Administration (OEP) and 
covers the ﬁ scal year of 2007. These data was analyzed in the light of different value of 
its average point. The Hungarian spa ﬁ nancing method is based on relative system, 
which is depending on the treatment’s price. We calculated the average health insurance 
subsidy per of spa treatment (HIS/STN) as an indicator of average health insurance 
reimbursement of a single spa treatment. RESULTS: In 2007 the number of spa treat-
ment was 8,160,438 and the full treatment expenditure of subsidy was 4.34 billion HUF 
(US$25,632 million). The average value of (HIS/STN) was 540,000 HUF (US$3124). 
Two outlier points are the region of North Hungarian Plan (different from average HIS/
STN value was −6.76%) and region of North Transdanubia (different from average 
HIS/STN value was 12.47%). The other regions performed similar outcomes ratio 
between 1.33% and 2.95%. CONCLUSIONS: The main cause of the two outlier 
regions is the inadequat structure of Spa services. Less people visit to North Transda-
nubian Region, because the number of spa facilities isn’t signiﬁ cant, but these thermal 
baths are signiﬁ cant, which price is higher. The North Hungarian Plan attracts a lot of 
patients with lower price. The result if the price is lower, the subsidy will be lower 
because of the ﬁ nancing system is based on relative method.
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OBJECTIVES: Achieving Market Access for new products has become complex for 
pharmaceutical companies. Faced with growing expenditure, health care authorities 
accept or propose various Market Access Agreements (MAA) (risk-sharing/perfor-
mance-based/commercial schemes) but often with little experience and knowledge. We 
performed in-depth analysis of their design and we formulate recommendations to 
stakeholders. METHODS: MAA is a formalized compromise between payers and 
industry to achieve: Price and Reimbursement, HTA recommendation and Formulary 
listing. We reviewed published and grey literature from major health insurers in 
France, Italy, Germany and UK. We conceptualize MAA typology according to the 
nature of uncertainty perceived by stakeholders and their motivations. RESULTS: We 
identiﬁ ed above 30 MAAs and classiﬁ ed them as follows: 1) Value for money not 
questioned: a) Conditional Market Access Agreement: Evidence development 
agreement→Aim: address actual uncertainty; b) Health Outcome Boostering Agree-
ment: Disease Management Initiative→Aim: improve competitive advantage; 2) Value 
for money questioned: a) Cost Containment Agreement: Basic commercial 
agreement→Aim: reduce/control drug bill; b) Health Outcomes Agreement: Value 
based agreement→Aim: link payment to performance. Motivations of public payers: 
Main: Buy health production; Other: Control expenditure; Improve ICER of expensive 
products; Prevent media coverage of negative decision; Provide patient access; Expand 
beneﬁ ts basket. Motivations of the industry: Main: Achieve Market Access for a 
product at high price in all markets; Other: Mitigate development failure; Reassure 
share holders; Improve company publicity; Fulﬁ l requirements of authorities. In UK 
the design of MAA was a direct consequence of formalized HTA, in Italy there was 
no apperent rationale. CONCLUSIONS: Commonly used nomenclature needs to be 
revisited. Applying our typology framework should allow health care payers and the 
industry to design and implement MAAs rationally and with transparence. MAAs in 
UK are a direct repercussion of a not favorable primary HTA.
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OBJECTIVES: ISPOR, iHEA, and HTAi regularly organize congresses in the ﬁ eld of 
health economics. Given the number of abstracts accepted each year it is crucial to assess 
their credibility and how results of cost-effectiveness analyses differ across meetings. 
METHODS: We collected all abstracts published 2007–2009 at ISPOR (International 
and Europe), HTAi and iHEA meetings. Abstracts on cost comparison, cost of treat-
ment, cost beneﬁ t, cost consequences, cost-effectiveness, cost minimization and cost 
utility analyses were reviewed in depth according to a reading grid which allowed 
extraction of essential information that could enable evidence-based decision-making in 
health policy. This included e.g. availability of key methodological parameters, involve-
ment of the industry in authorship and details of conclusions. RESULTS: We analyzed 
5488 abstracts from ISPOR, 1410 from HTAi and 1969 from iHEA. Our preliminary 
